Comparison of piroxicam and Satureja Khuzestanica essential oils and extracts in reducing pain in patients with osteoarthritis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138902043760N2

Enrollment

245

Registered

2014-10-20

Start date

2012-07-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Analgesic. Condition 2: Arthrosis. Condition 3: osteoarthrosis. Analgesic, antipyretic and anti-inflammatory drug, unspecified Arthrosis, unspecified Erosive (osteo)arthrosis

Interventions

Intervention 1: Control group: receive piroxicom b.i.d Up to two weeks. Intervention 2: Intervention group: receive the essential oil of Satureja khuzestanica 1% b.i.d Up to two weeks. Interventio

Treatment - Drugs

Control group: receive piroxicom b.i.d Up to two weeks

Intervention group: receive the essential oil of Satureja khuzestanica 1% b.i.d Up to two weeks

Intervention group: receive the essential oil of Satureja khuzestanica 3% b.i.d Up to two weeks

Intervention group: receive the essential oil of Satureja khuzestanica 6% b.i.d Up to two weeks

Intervention group: receive the extract of Satureja khuzestanica 1% b.i.d Up to two weeks

Intervention group: receive the extract of Satureja khuzestanica 3% b.i.d Up to two weeks

Intervention group: receive the extract of Satureja khuzestanica 6% b.i.d Up to two weeks

Control group: receive Eucerin b.i.d Up to two weeks

Eligibility

Sex/Gender

All

Age

30 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria:Women and men over 30 years of age with osteoarthritis. Exclusion criteria:Patients who use steroid injections? edible medications or local sedative? Pregnant Women? Women who are breastfeeding? Patients who are sensitive to the Satureja Khozestanica.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: 0,7,14. Method of measurement: VAS.	—

Secondary

Measure	Time frame
Skin irritation. Timepoint: Days 1,7,14. Method of measurement: VAS questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Rashidipour

Lorestan University of Medical Sciences

m_rashidi80@yahoo.com+98 66 3320 4005

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026